Size exclusion chromatography as green support for forced degradation study of adalimumab

1 V. Jairath and B. G. Feagan, Global burden of inflammatory bowel disease, Lancet Gastroenterol. Hepatol. 5(1) (2020) 2–3; https://doi.org/10.1016/S2468-1253(19)30358-9 Search in Google Scholar

2 R. Ratih, M. Asmari, A. M. Abdel-Megied, F. Elbarbry and S. El Deeb, Biosimilars: review of regulatory, manufacturing, analytical aspects and beyond, Microchem. J. 165 (2021) Article ID 106143 (10 pages); https://doi.org/10.1016/j.microc.2021.106143 Search in Google Scholar

3 G. R. D’Haens and S. van Deventer, 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future, Gut 70 (2021) 1396–1405; http://dx.doi.org/10.1136/gutjnl-2019-320022 Search in Google Scholar

4 R. Atreya, M. F. Neurath and B. Siegmund, Personalizing treatment in IBD: Hype or reality in 2020? Can we predict response to anti-TNF?, Front Med. (Lausanne) 7 (2020) Article ID 517 (14 pages); https://doi.org/10.3389/fmed.2020.00517 Search in Google Scholar

5 M. Sajid and J. Płotka-Wasylka, Green analytical chemistry metrics: a review, Talanta 238 (2022) 123046; https://doi.org/10.1016/j.talanta.2021.123046 Search in Google Scholar

6 S. M. Singh, R. Furman, R. K. Singh, G. Balakrishnan, N. Chennamsetty, L. Tao and Z. Li, Size exclusion chromatography for the characterization and quality control of biologics, J. Liq. Chromatogr. Relat. Technol. 44(5-6) (2021) 265–278; https://doi.org/10.1080/10826076.2021.1979582 Search in Google Scholar

7 European Directorate for the Quality of Medicines & HealthCare (EDQM) Council of Europe, Technical Guide for the Elaboration of Monographs on Synthetic Peptides and Recombinant DNA Proteins, in European Pharmacopoeia, 2^nd revision ed., Strasbourg 2018, pp. 5–15; https://www.edqm.eu/en/d/67217 Search in Google Scholar

8 A. Goyon, S. Fekete, A. Beck, J.-L. Veuthey and D. Guillarme, Unraveling the mysteries of modern size exclusion chromatography – the way to achieve confident characterization of therapeutic proteins, J. Chromatogr. B 1092 (2018) 368–378; https://doi.org/10.1016/j.jchromb.2018.06.029 Search in Google Scholar

9 T. Kohno, L.-T. T. Tam, S. R. Stevens and J. S. Louie, Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs, J. Investig. Dermatol. Symp. Proc. 12(1) (2007) 5–8; https://doi.org/10.1038/sj.jidsymp.5650034 Search in Google Scholar

10 N. Lee, I. J. J. Lee, H. Yang, S. Baek, S. Kim, S. Kim, T. Lee, D. Song and G. Park, Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab, MAbs 11(1) (2018) 129–144; https://doi.org/10.1080/19420862.2018.1530920 Search in Google Scholar

11 S. Schreiber, K. Yamamoto, R. Muniz and T. Iwura, Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab, Pharmacol. Res. Perspect 8(3) (2020) e00604 (13 pages); https://doi.org/10.1002/prp2.604 Search in Google Scholar

12 Y. Jiang, T. Arora, S. Klakamp, J. Davis, Y. A. Chandrasekher, G. Young, Y. Du, B. Yu and K. J. Miller, Demonstration of physicochemical and functional similarity of biosimilar adalimumabaqvh to adalimumab, Drugs in R&D 23 (2023) 377–395; https://doi.org/10.1007/s40268-023-00437-3 Search in Google Scholar

13 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH guideline Q2(R2) on validation of analytical procedures; https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q2r2-validation-analytical-procedures-step-2b_en.pdf; last access date September 22, 2023. Search in Google Scholar

14 F. Pena-Pereira, W. Wojnowski and M. Tobiszewski, AGREE—Analytical GREEnness metric approach and software, Anal. Chem. 92(14) (2020) 10076–10082; https://doi.org/10.1021/acs.analchem.0c01887 Search in Google Scholar

15 The United States Pharmacopeia and The National Formulary, 2021 (USP-NF2021), United States Pharmacopeial Convention, Rockville, MD, 2021. Search in Google Scholar

16 C. Nowak, J. K. Cheung, S. M. Dellatore, A. Katiyar, R. Bhat, J. Sun, G. Ponniah, A. Neill, B. Mason, A. Beck, and H. Liu, Forced degradation of recombinant monoclonal antibodies: A practical guide, MAbs 9(8) (2017) 1217–1230; https://doi:10.1080/19420862.2017.1368602 Search in Google Scholar

17 L. A. Hassan, M. A. Al-Ghobashy and S. S. Abbas, Evaluation of the pattern and kinetics of degradation of adalimumab using a stability-indicating orthogonal testing protocol, Biomed. Chromatogr. 33(12) (2019) e4676; https://doi:10.1002/bmc.4676 Search in Google Scholar

18 A. B. Shabestari, S. M. Mostafavi and H. Malekzadeh, Force degradation comparative study on biosimilar adalimumab and Humira, Rev. Latinoam. Hipertens. 13(6) (2018) 496–508. Search in Google Scholar

19 F. Füssl, A. Trappe, K. Cook, K. Scheffler, O. Fitzgerald and J. Bones, Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry, MAbs 11(1) (2019) 116–128; https://doi.org/10.1080/19420862.2018.1531664 Search in Google Scholar

20 R. E. Hariry, R. V. Barenji and A. Azizi, Toward Pharma 4.0 in Drug Discovery, in Industry 4.0. Emerging Trends in Mechatronics (Ed. A. Azizi, R. V. Barenji) Springer, Singapore 2023; https://doi.org/10.1007/978-981-19-2012-7_10 Search in Google Scholar

21 J. Kovačić, M.-L. Jeličić, D. Amidžić Klarić and A. Mornar, Green solid-phase (micro)extraction of andrographolides’ from human plasma samples followed by UHPLC-DAD-QqQ-MS/MS analysis, Separations 10(2) (2023) Article ID 69 (18 pages); https://doi.org/10.3390/separations10020069 Search in Google Scholar